Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Dose-Comparison Study to Determine the Efficacy and Safety of BG00012 in Subjects With Relapsing-Remitting Multiple Sclerosis
Brief Summary: To determine if treatment with BG00012 can decrease the number of MS relapses during a certain time period. To determine if, over time, BG00012 treatment can decrease the number of certain types of brain lesions commonly seen in MS patients and slow down the time it takes for the disease to get worse.

The purpose of this study is also to determine the safety of BG00012 and how well it is tolerated. Another goal is to see what effect BG00012 may have on tests and evaluations used to assess MS.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: BG00012 240 mg Twice Daily (BID); Type: EXPERIMENTAL; Interventions: Drug: BG00012 | Arm Label: BG00012 240 mg 3 Times Daily (TID); Type: EXPERIMENTAL; Interventions: Drug: BG00012 | Intervention Type: DRUG; Name: BG00012; Assigned to Arm(s): BG00012 240 mg 3 Times Daily (TID), BG00012 240 mg Twice Daily (BID) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Cohort 1; Type: EXPERIMENTAL; Interventions: Drug: Ofatumumab 3mg, Drug: Placebo | Arm Label: Cohort 2; Type: EXPERIMENTAL; Interventions: Drug: Ofatumumab 3mg, Drug: Placebo | Arm Label: Cohort 3.1; Type: EXPERIMENTAL; Interventions: Drug: Ofatumumab 30mg, Drug: Placebo | Arm Label: Cohort 3.2; Type: EXPERIMENTAL; Interventions: Drug: Ofatumumab 3mg, Drug: Ofatumumab 30mg, Drug: Placebo | Arm Label: Cohort 4.1; Type: EXPERIMENTAL; Interventions: Drug: Ofatumumab 60mg, Drug: Placebo | Arm Label: Cohort 4.2; Type: EXPERIMENTAL; Interventions: Drug: Ofatumumab 3mg, Drug: Ofatumumab 60mg, Drug: Placebo | Arm Label: Cohort 5.1; Type: EXPERIMENTAL; Interventions: Drug: Ofatumumab 60mg, Drug: Placebo | Arm Label: Cohort 5.2; Type: EXPERIMENTAL; Interventions: Drug: Ofatumumab 3mg, Drug: Ofatumumab 60mg | Intervention Type: DRUG; Name: Ofatumumab 3mg; Assigned to Arm(s): Cohort 1, Cohort 2, Cohort 3.2, Cohort 4.2, Cohort 5.2 | Intervention Type: DRUG; Name: Ofatumumab 30mg; Assigned to Arm(s): Cohort 3.1, Cohort 3.2 | Intervention Type: DRUG; Name: Ofatumumab 60mg; Assigned to Arm(s): Cohort 4.1, Cohort 4.2, Cohort 5.1, Cohort 5.2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cohort 1, Cohort 2, Cohort 3.1, Cohort 3.2, Cohort 4.1, Cohort 4.2, Cohort 5.1
C: Arm Label: BG00012 240 mg Twice Daily (BID); Type: EXPERIMENTAL; Interventions: Drug: BG00012, Drug: Placebo | Arm Label: BG00012 240 mg 3 Times Daily (TID); Type: EXPERIMENTAL; Interventions: Drug: BG00012 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Glatiramer Acetate (GA) 20 mg Injection Once Daily (QD); Type: ACTIVE_COMPARATOR; Interventions: Drug: Glatiramer Acetate | Intervention Type: DRUG; Name: BG00012; Assigned to Arm(s): BG00012 240 mg 3 Times Daily (TID), BG00012 240 mg Twice Daily (BID) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): BG00012 240 mg Twice Daily (BID), Placebo | Intervention Type: DRUG; Name: Glatiramer Acetate; Assigned to Arm(s): Glatiramer Acetate (GA) 20 mg Injection Once Daily (QD)
D: Arm Label: Daclizumab High Yield Process 150 mg SC; Type: EXPERIMENTAL; Interventions: Biological: BIIB019 (Daclizumab High Yield Process), Drug: Interferon beta-1a Placebo | Arm Label: IFN β-1a 30 µg IM; Type: ACTIVE_COMPARATOR; Interventions: Biological: Interferon beta-1a, Drug: Daclizumab High Yield Process Placebo | Intervention Type: BIOLOGICAL; Name: BIIB019 (Daclizumab High Yield Process); Assigned to Arm(s): Daclizumab High Yield Process 150 mg SC | Intervention Type: DRUG; Name: Interferon beta-1a Placebo; Assigned to Arm(s): Daclizumab High Yield Process 150 mg SC | Intervention Type: BIOLOGICAL; Name: Interferon beta-1a; Assigned to Arm(s): IFN β-1a 30 µg IM | Intervention Type: DRUG; Name: Daclizumab High Yield Process Placebo; Assigned to Arm(s): IFN β-1a 30 µg IM

Answer: A